Treatment Outcome of Proliferative Diabetic Retinopathy Management in Thailand: A Retrospective Study (Today Study)
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
摘要
Introduction: The study aimed to assess real-world treatment outcomes of proliferative diabetic retinopathy (PDR) in terms of visual acuity (VA) change after pan-retinal photocoagulation (PRP) with adjunct treatments and clinical burden in Thailand.
Methods: Multi-center retrospective medical review of the patients with PDR who received the first PRP from 1 June 2016 to 30 June 2019 with at least 1-year follow-up data.
Result: 359 patients were included. Mean change in ETDRS letters VA declined at year 1 (-2.44, 95% confidence interval [CI] -4.54 to -0.34, p = 0.023), year 2 (-3.52, 95%CI –6.85 to -0.18, p = 0.039) and year 3 (-7.38, 95%CI -13.77 to -0.99, p = 0.024). Of all 359 patients, 162 patients (45.13%) had PRP monotherapy, 164 patients (45.68%) had adjunctive anti-vascular endothelial growth factor treatments and a few had other adjunctive treatments. The median number of visits to complete PRP is 3, with a total of 8 visits within one year.
Conclusion: This study demonstrates real-world outcomes of a decline in VA following PRP in patients with PDR in Thailand. Due to the nature of retrospective study and lack of confounding control in this study, the results should be interpreted with caution. Adjunctive treatments were common in patients with PDR.
Conflicts of interest: This study was sponsored by Novartis (Thailand) Ltd.
##plugins.themes.bootstrap3.article.details##
参考
Ferris FL, 3rd. Results of 20 years of research on the treatment of diabetic retinopathy. Prev Med. 1994;23(5):740-2.
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124-36.
Chaudhary S, Zaveri J, Becker N. Proliferative diabetic retinopathy (PDR). Dis Mon. 2021;67(5):101140.
Singh R, Ramasamy K, Abraham C, Gupta V, Gupta A. Diabetic retinopathy: an update. Indian J Ophthalmol. 2008;56(3):178-88.
Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology. 1981;88:583–600.
Early treatment diabetic retinopathy study research group early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991;98(5 Suppl):766–85.
Gross JG, Glassman AR, Liu D, et al. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA Ophthalmol. 2018;136:1138.
Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, et al. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA. 2015;314(20):2137.
Figueira J, Fletcher E, Massin P, et al. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study). Ophthalmology. 2018;125(5):691-700.
Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789-801.
Flynn Jr HW, Chew EY, Simons BD, Barton FB, Remaley NA, Ferris FL. Pars plana vitrectomy in the early treatment diabetic retinopathy study. ETDRS report number 17. The early treatment diabetic retinopathy study research group. Ophthalmology. 1992;99:1351–7.
